AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HROW · NASDAQ · Drug Manufacturers - Specialty & Generic

Harrow (HROW)

Commercializes branded eye medicines and ImprimisRx compounding for US ophthalmology.

$33.86

vs last close−0.59 (−1.71%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	34	36	35	49	49	67	48	64	72	89	44	71
Cost of revenue	10	11	11	13	12	14	16	16	18	18	17	20
Gross profit	24	25	24	36	37	53	32	48	54	71	27	50
	22	30	31	35	36	40	44	36	39	47	49	61
Research & development	1	3	2	3	2	5	3	3	3	3	6	8
	0	0	0	0	0	0	0	0	0	43	43	53
General & administrative	0	0	0	0	0	0	0	0	0	0	0	53
Other expenses	21	27	29	32	34	35	41	33	36	0	0	0
Operating income	2	−5	−7	2	1	13	−11	11	15	24	−22	−11
	−5	−5	−7	−7	−6	−7	−7	−6	−14	−14	−5	−6
Interest expense	6	5	5	5	6	6	7	6	6	5	5	6
Other non-operating income	0	0	1	2	0	0	0	0	8	8	0	0
Income before tax	−3	−10	−14	−6	−4	6	−18	5	1	10	−28	−17
Income tax expense	2	−1	0	1	0	−1	0	0	0	4	0	0
Net income from continuing operations	−4	−9	−14	−6	−4	7	−18	5	1	7	−28	−17
Net income	−4	−9	−14	−6	−4	7	−18	5	1	7	−28	−17
EPS, basic	−$0.13	−$0.26	−$0.38	−$0.18	−$0.12	$0.19	−$0.50	$0.14	$0.03	$0.18	−$0.74	−$0.46
EPS, diluted	−$0.13	−$0.26	−$0.38	−$0.18	−$0.12	$0.19	−$0.50	$0.13	$0.03	$0.18	−$0.74	−$0.46
Weighted average shares, basic	34	35	35	36	36	36	36	37	37	37	37	37
Weighted average shares, diluted	34	35	35	36	36	36	36	39	39	37	37	37
EBITDA	5	−2	−5	3	4	18	−7	16	12	20	−16	−11
Depreciation & amortization	3	3	3	3	3	4	5	5	5	5	6	0
EBIT	2	−4	−8	0	1	13	−11	11	7	16	−22	−11